AlzeCure’s ACD856’s effects to be presented at Alzheimer’s conference

Preclinical data on NeuroRestore therapy to be showcased at CTAD in Madrid

AlzeCure Pharma AB, a company specializing in drugs for nervous system diseases, announced that its abstract on NeuroRestore ACD856 has been accepted for presentation at the Clinical Trials in Alzheimer’s Disease (CTAD) conference.

The event will take place in Madrid, Spain, from October 29 to November 1.

The abstract, titled ‘Preclinical evidence for anti-inflammatory and immunomodulatory effects of NeuroRestore ACD856, a Trk-PAM in clinical development for the treatment of Alzheimer’s disease’, will be presented by Dr Cristina Parrado-Fernández, Senior Scientist at AlzeCure. The research team includes experts from AlzeCure Pharma and Karolinska Institutet.

The presentation will highlight new preclinical results showing that ACD856, the lead candidate in the NeuroRestore platform, exhibits both anti-inflammatory and immunomodulating properties.

These effects have been observed in aged animals and Alzheimer’s models, suggesting potential disease-modifying properties.

Previous studies have demonstrated that AlzeCure’s NeuroRestore candidates enhance communication between nerve cells and improve cognitive functions such as learning and memory.

The unique pharmacological mechanism of NeuroRestore supports its use in multiple indications, including Alzheimer’s, Parkinson’s disease, and depression. ACD856 is currently being prepared for Phase II clinical studies in Alzheimer’s patients.

Martin Jönsson, CEO of AlzeCure Pharma, emphasized the significance of these findings and the recognition from the CTAD conference.

He stated that the promising results further validate the potential of ACD856 as a disease-modifying treatment and underscore the company’s commitment to advancing research in neurodegenerative diseases.

The acceptance of this abstract at CTAD is seen as a validation of AlzeCure’s innovative approach and the NeuroRestore platform, positioning the company at the forefront of Alzheimer’s research.